The global blood group typing market size was estimated to be US$ 3.5 billion in 2021 and is expected to grow at a CAGR of 9.3% between 2023 to 2032.
The blood group typing market continued to be influenced by the key drivers, progress in new product development, and the introduction of exciting technologies.
Research and development for new products started as early as 1946, with a fundamental goal of keeping blood transfusion going despite wartime shortages. Thus, iMED proved that donor blood units identified initially as A- were another (later) AB Rhesus phenotype; this accurate match was not previously possible based on antigens alone.
Additional binding properties were revealed by analysis of human erythrocytes using electrophoresis. This work transformed our understanding of all aspects of ABO compatibility. It ultimately led to the control by all transfusion services worldwide of donor-type OPO, which was first developed in 1959 and became a standard operating procedure in 1970.
People worldwide have different blood pressure; this is generally classified into four types.
ABO Factor: these are genetically determined variations in the genes which encode A or B antigens on red blood cells. Their underlying alleles determine a person's blood group at one of six genes, three with gene locus (A, B, or G) and three with gene loci (IA, IB, and II). The most important blood groups from a clinical point of view are ABO and Rh(D?).
ABO typing is possible through either native DNA sequence as a template for PCR amplification using cloned alleles as hybridization probes to produce localized DNA sequences or indirect phenotyping done on serum antibodies.
The high auto-segmentation reaction of high-tritium cattle that identifies six genotypes in ABO/E(P) typing provides one of the best breeds for bovine genomic variety research.
The number of people worldwide who require blood transfusions is gradually increasing. Centralized blood banks are short of supplies due to geographical location, population density, and severity of war or medical accidents. Transfusions from matched donors are required for patients with severe hereditary diseases, such as thalassemia or sickle cell anemia, who need constant transfusions throughout their lives. To ensure the success rate, ABO-typing is required to ensure that the donor's and recipient's blood groups are compatible.
Type O is the most common type in the world, and you can donate to other O's if there is a shortage. Type AB can contribute to all groups but only receives from other ABs. Type A can only receive from other AAs and will not donate because they lack type B antigens, indicating type A activity; an individual with traits for both A1 and A2 actions will.
The quantity of blood donations collected globally has increased over time. The demand for blood group identification and cross-matching procedures for transfusion has increased due to an increase in voluntary blood donations. The boost in blood donations during the projection period is expected to increase the number of these operations, which will fuel market expansion.
Additionally, there has been an increase in demand for blood and blood components in all areas for a variety of surgical and medicinal procedures. Additionally, the rise in government campaigns to raise public awareness of the benefits of voluntary blood donations helps explain why more people will donate during the forecast period.
Instruments and reagents & kits are two product categories that may be used to segment the worldwide market. Due to the widespread usage of these items in various processes, the reagents & kits sector dominated the market. One of the leading causes of segmental enlargement is the rising amount of blood donors and transfusions. The instruments segment is expected to see good growth possibilities during the projection period. Technology developments, strategic efforts, and increased use of sophisticated instruments for these operations are expected to boost industry growth.
The global market can be divided into ABO tests, antigen typing, antibody screening, cross-matching tests, and HLA typing based on test type. Due to an increase in blood transfusions, a rise in the prevalence of chronic diseases, and prenatal testing, the antibody screening segment dominated the market. Pregnant patients need to undergo several screening tests, such as blood group and antibody screening. Prenatal testing is becoming more common, accelerating the segment's growth.
As they are used for identifying and matching organ and tissue donation operations in the region, cross-matching tests and HLA typing are also expected to expand with a sizable CAGR.
Serology testing and molecular tests are two market segments depending on technology. Due to increasing efforts to encourage voluntary blood donations and new product introductions, the serology testing category had a disproportionately large percentage of the worldwide blood group typing market. One of the more established techniques in this sector is serology testing, which may be applied in a lab setting or during a research project. Additionally, they are accessible and straightforward, which fuels the market's desire for these goods.
Because molecular testing is becoming increasingly popular, their market is expected to expand significantly. The main driver of the segment's growth is the strong sensitivity of molecular tests to detection.
The market is divided into independent labs & blood banks, and hospital-based laboratories depending on the end-user. Due to an increase in independent labs and blood banks, notably in emerging nations, this market sector, which now holds a monopoly, is anticipated to expand.
Hospital-based laboratories make up the second-largest market share in terms of end users. During the forecast period, the segmental expansion will be aided by favorable reimbursement policies and the growing number of hospitals in developed nations.
The worldwide market is researched in North America, Europe, Asia Pacific, South America, the Middle East, and Africa, depending on geography.
North America market is expected to dominate worldwide during the projected period. Due to the increasing demand for blood transfusions, increased use of automated blood typing equipment, and supportive reimbursement rules for these operations, the area leads the industry. Additionally, North America market expansion is driven by regulatory approvals for worldly goods.
In 2021, the Europe area had the second-largest market share. An increase in these procedures and public awareness of the importance of blood donations will primarily drive the market.
Due to increased R&D efforts to provide enhanced blood group typing technologies, the Asia Pacific market is anticipated to rise significantly. It is hoped that such R & D activities will introduce unique products in Japan. Due to increasing awareness of blood and organ donation in Brazil, the South American industry has been expanding. During the projection period, South America's developing blood-collecting infrastructure will significantly support market expansion.
Due to rising awareness of blood donations and an increase in blood transfusions in hospital trauma centers, the Middle East and Africa area is predicted to have growth potential throughout the projection period.
The absence of infrastructure for blood group typing, particularly in developing nations, significantly inhibits market expansion despite the high demand for blood donation and transfusion operations among the patient population.
Long travel distances between hospitals and centralised services, infrastructural problems including an unstable electrical supply, and a lack of governmental backing as obstacles to blood donation and transfusion processes are some other contributing reasons. Additionally, emerging nations have lax regulations regarding payment for these operations. This raises the financial obstacles, which lowers the testing rates. As a result, and as previously discussed, these constraints may limit market expansion throughout the anticipated time frame.
Grifols, S.A., Bio-Rad Laboratories, Inc., Immucor, Ortho Clinical Diagnostics, Quotient, BAG Health Care GmbH, Sucuri, AXO Science, Agena Bioscience, Inc., Beckman Coulter, Inc., Grifols S.A., Novacyt Group, Ortho Clinical Diagnostics, DIAGAST, and Agena Bioscience Inc. are a few of the major companies operating in the blood group typing industry.
By Technique:
By Test Type:
By End-use:
By Geography
The global blood group typing market is estimated to exhibit a CAGR of 9.3% between 2023 to 2032.
The blood group typing market size was estimated to be US$ 3.5 billion in 2021.
From 2023 to 2032, Asia Pacific will experience the fastest growth rate.
Grifols, S.A., Bio-Rad Laboratories, Inc., Immucor, Ortho Clinical Diagnostics, Quotient, BAG Health Care GmbH, Sucuri, AXO Science, Agena Bioscience, Inc., Beckman Coulter, Inc., Grifols S.A., Novacyt Group, Ortho Clinical Diagnostics, DIAGAST, Agena Bioscience Inc. among others, are the key players in this market.
North America accounted for over 30% of global business in 2021 and will continue to expand as a result of the region's strong industrial presence, high healthcare spending, and regulatory approvals of cutting-edge technology.
Since antigen testing has a quicker turnaround time, is more affordable, and is simple to use, demand is expected to increase. This segment had a more than 20% revenue share in 2021.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved